These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 25501377)
1. Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria. Wu KCP; Jabbar-Lopez ZK J Invest Dermatol; 2015 Jan; 135(1):13-15. PubMed ID: 25501377 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. Saini SS; Bindslev-Jensen C; Maurer M; Grob JJ; Bülbül Baskan E; Bradley MS; Canvin J; Rahmaoui A; Georgiou P; Alpan O; Spector S; Rosén K J Invest Dermatol; 2015 Jan; 135(1):67-75. PubMed ID: 25046337 [TBL] [Abstract][Full Text] [Related]
3. Ligelizumab for Chronic Spontaneous Urticaria. Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874 [TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974 [TBL] [Abstract][Full Text] [Related]
5. Omalizumab: a review of its use in patients with chronic spontaneous urticaria. McCormack PL Drugs; 2014 Sep; 74(14):1693-9. PubMed ID: 25217402 [TBL] [Abstract][Full Text] [Related]
6. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. Metz M; Ohanyan T; Church MK; Maurer M J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603 [TBL] [Abstract][Full Text] [Related]
7. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized. Uysal P; Eller E; Mortz CG; Bindslev-Jensen C J Allergy Clin Immunol; 2014 Mar; 133(3):914-5.e2. PubMed ID: 24360324 [No Abstract] [Full Text] [Related]
8. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116 [TBL] [Abstract][Full Text] [Related]
9. Omalizumab for the treatment of chronic urticaria. Zuberbier T; Maurer M Expert Rev Clin Immunol; 2015 Feb; 11(2):171-80. PubMed ID: 25566680 [TBL] [Abstract][Full Text] [Related]
10. Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test. Rodríguez-Trabado A; Fernández Pereira LM; Romero-Chala S; García-Trujillo JA; Cámara Hijón C Allergol Immunopathol (Madr); 2012; 40(6):390-2. PubMed ID: 22178123 [No Abstract] [Full Text] [Related]
11. Successful treatment of a bullous urticaria with omalizumab. Ozturk AB; Kocaturk E; Ozturk E Allergol Int; 2014 Sep; 63(3):495-7. PubMed ID: 24957115 [No Abstract] [Full Text] [Related]
12. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097 [TBL] [Abstract][Full Text] [Related]
13. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Zazzali JL; Kaplan A; Maurer M; Raimundo K; Trzaskoma B; Solari PG; Antonova E; Mendelson M; Rosén KE Ann Allergy Asthma Immunol; 2016 Oct; 117(4):370-377.e1. PubMed ID: 27424128 [TBL] [Abstract][Full Text] [Related]
14. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. Maurer M; Rosén K; Hsieh HJ; Saini S; Grattan C; Gimenéz-Arnau A; Agarwal S; Doyle R; Canvin J; Kaplan A; Casale T N Engl J Med; 2013 Mar; 368(10):924-35. PubMed ID: 23432142 [TBL] [Abstract][Full Text] [Related]
15. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177 [TBL] [Abstract][Full Text] [Related]
16. Omalizumab in the treatment of chronic urticaria. Francés L; Leiva-Salinas M; Silvestre JF Actas Dermosifiliogr; 2014; 105(1):45-52. PubMed ID: 23938072 [TBL] [Abstract][Full Text] [Related]
17. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957 [TBL] [Abstract][Full Text] [Related]